This phase I study is evaluating how safe, tolerable and effective a new targeted therapy (CC-95251) is alone, and in combination with another drug (azacitidine) in people with relapsed or refractory acute myeloid leukaemia, and people with myelodysplastic syndromes.
This trial is treating patients with acute myeloid leukaemia and myelodyspastic syndromes.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bristol-Myers Squibb (BMS)
Eligible participants will be allocated to one of two experimental arms. In Experimental Arm A, participants will receive CC-95251 as monotherapy. In Experimental Arm B, participants will receive CC-95251 in combination with azacitidine.
Recruiting Hospitals Read More